Exact Sciences Corp. announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, "Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights," affirms that the Oncotype DX test provides accurate and reliable information to help guide breast cancer treatment decisions across all racial and ethnic groups.
While breast cancer mortality has declined overall, non-Hispanic Black women continue to face a 40% higher mortality rate compared to non-Hispanic White womenI. Despite the prognostic differences between racial and ethnic minority groups, the Oncoytpe DX Breast Recurrence Score test accurately predicts chemotherapy benefit regardless of race or ethnicity. While these disparities highlight the need for broader systemic change, advancing precision oncology remains critical and tools like the Oncotype DX breast Recurrence Score test ensure treatment decisions are guided by reliable data for every patient.
The largest real-world SEER registry analysis to date--spanning more than 171,000 breast cancer patients and presented at ASCO 2024--provides powerful new evidence that the Oncotype DX tests accurately predicts chemotherapy benefit across all racial and ethnic groups; In this study, which is not part of the JAMA Oncology review, the Recurrence Score result predicted chemotherapy benefit in Hispanic, non-Hispanic Black and non-Hispanic White patients; These findings add to the body of evidence from key clinical trials--including NSABP-B20 and SWOG+-8814--which confirm that Oncotype DX is the only genomic test proven to predict chemotherapy benefit, the utility of which was further confirmed in randomized clinical trials including TAILORx and RxPONDER III,IV. With no racial or ethnic differences shown in its predictive value, the Oncotype DX test remains a trusted tool to help guide breast cancer treatment decision for all patients. Key Highlights: This publication reinforces the Oncotype DX test's value in helping guide treatment decisions--providing precise estimates of distant recurrence risk and accurately identifying which breast cancer patients may or may not benefit from chemotherapy, regardless of race or ethnicity; Secondary analyses of TAILORx and Rx PONDER, which included the Oncotype DX Breast recurrence Score test, confirm consistent chemotherapy benefit across racial and ethnic groups,highlighting that worse prognostic outcomes do not necessarily translate to greater chemotherapy benefitV.
The paper suggests that continued research is essential to understanding the biological, social, and systemic drivers of disparities in breast cancer outcomes--and to ensuring equitable access to genomic tools like the OncotypeDX test. National Surgical Adjuvant Breast and Bowel Project+ SWOG is part of the National Cancer Institute's National Clinical Trials Network; references I. Giaquinto AN, Sung H, Miller KD, et al. Breast Cancer Statistics, 2022.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps give patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuuuuu-SIA-B20 and SWOG-8814; and SWOG-8814.
